HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

Abstract
Activating mutations in tyrosine kinases have been identified in hematopoietic and nonhematopoietic malignancies. Recently, we and others identified a single recurrent somatic activating mutation (JAK2V617F) in the Janus kinase 2 (JAK2) tyrosine kinase in the myeloproliferative disorders (MPDs) polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. We used direct sequence analysis to determine if the JAK2V617F mutation was present in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML)/atypical chronic myelogenous leukemia (aCML), myelodysplastic syndrome (MDS), B-lineage acute lymphoblastic leukemia (ALL), T-cell ALL, and chronic lymphocytic leukemia (CLL). Analysis of 222 patients with AML identified JAK2V617F mutations in 4 patients with AML, 3 of whom had a preceding MPD. JAK2V617F mutations were identified in 9 (7.8%) of 116 CMML/a CML samples, and in 2 (4.2%) of 48 MDS samples. We did not identify the JAK2V617F disease allele in B-lineage ALL (n = 83), T-cell ALL (n = 93), or CLL (n = 45). These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies.
AuthorsRoss L Levine, Marc Loriaux, Brian J P Huntly, Mignon L Loh, Miroslav Beran, Eric Stoffregen, Roland Berger, Jennifer J Clark, Stephanie G Willis, Kim T Nguyen, Nikki J Flores, Elihu Estey, Norbert Gattermann, Scott Armstrong, A Thomas Look, James D Griffin, Olivier A Bernard, Michael C Heinrich, D Gary Gilliland, Brian Druker, Michael W N Deininger
JournalBlood (Blood) Vol. 106 Issue 10 Pg. 3377-9 (Nov 15 2005) ISSN: 0006-4971 [Print] United States
PMID16081687 (Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Proto-Oncogene Proteins
  • Protein-Tyrosine Kinases
  • JAK2 protein, human
  • Janus Kinase 2
Topics
  • Aged
  • Alleles
  • Amino Acid Substitution
  • Case-Control Studies
  • Enzyme Activation (genetics)
  • Female
  • Humans
  • Janus Kinase 2
  • Leukemia, Lymphocytic, Chronic, B-Cell (enzymology, genetics)
  • Leukemia, Lymphoid (enzymology, genetics)
  • Leukemia, Myeloid (enzymology, genetics)
  • Leukemia, Myelomonocytic, Chronic (enzymology, genetics)
  • Male
  • Middle Aged
  • Point Mutation
  • Protein-Tyrosine Kinases (genetics, metabolism)
  • Proto-Oncogene Proteins (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: